Pharmacokinetic Effect of Y-3 on Repaglinide，Warfarin and Omeprazole in Healthy Participants

NCT07068841 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Pharmacokinetic Profiles
Y-3 for Injection
Drug-drug Interaction
Repaglinide Tablets
Warfarin Sodium Tablets
Omeprazole Enteric-coated Capsules
Safty

Interventions

DRUG: sequentially single use of repaglinide, warfarin and omeprazole or combined with Y-3

Sponsor

Neurodawn Pharmaceutical Co., Ltd.